Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Rajavithi Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Rajavithi Hospital
ClinicalTrials.gov Identifier:
NCT01546376
First received: March 2, 2012
Last updated: March 6, 2012
Last verified: January 2009
  Purpose

Objectives: To study immunostatus (CD4) and HIV viral load in HIV-cancer patients before RT and last weeks of RT .


Condition Intervention
To Study Immunostatus of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT
To Study HIV Viral Load of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT
Radiation: Radiation therapy
Other: Venepuncture

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients

Resource links provided by NLM:


Further study details as provided by Rajavithi Hospital:

Estimated Enrollment: 100
Study Start Date: August 2009
Groups/Cohorts Assigned Interventions
HIV-cancer patients who recived RT Radiation: Radiation therapy
External photon beam radiation therapy dosage 4000-7000 CGy
Other: Venepuncture
Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

HIV positive cancer patients Curative RT treatment

Criteria

Inclusion Criteria:

  • Age 18-65 years
  • HIV positive cancer patients
  • Photon beam RT, conventional fraction >= 4000 cgy in 4 weeks

Exclusion Criteria:

  • CD4 count < 200 cell/ml and not received anti retro viral
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01546376

Contacts
Contact: Pathomphorn Siraprapasiri, MD 66-89-6662960 spathomphorm@gmail.com

Locations
Thailand
Rajavithi Hospital Recruiting
Bangkok, Thailand, 10400
Contact: Pathomphorn Siraprapasiri, MD    66-89-6662960    spathomphorn@gmail.com   
Sponsors and Collaborators
Rajavithi Hospital
  More Information

No publications provided

Responsible Party: Rajavithi Hospital
ClinicalTrials.gov Identifier: NCT01546376     History of Changes
Other Study ID Numbers: THAIHIV001
Study First Received: March 2, 2012
Last Updated: March 6, 2012
Health Authority: Thailand: Thai Society of radiation oncology
Thailand: Rajavithi Hospital

ClinicalTrials.gov processed this record on November 25, 2014